AbbVie, Genmab Lymphoma Treatment Gets European Commission Marketing Authorization
By Denny Jacob
AbbVie and Genmab disclosed that the European Commission granted conditional marketing authorization for Tepkinly to treat relapsed or refractory follicular lymphoma in adults.
Follicular lymphoma is an incurable form of non-Hodgkin's lymphoma with about 13,000 estimated cases in Western Europe alone each year, according to the drugmakers.
AbbVie specified the treatment's authorization is for adults after two or more lines or prior therapy. It added that the authorization is supported by data from a Phase 1/2 clinical trial.
Tepkinly is being co-developed by AbbVie and Genmab as part of the companies' oncology collaboration.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
August 19, 2024 14:54 ET (18:54 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
10 Top-Performing Dividend Stocks of Q3 2024
-
33 Undervalued Stocks
-
Communication Services: Cable’s Broadband Dominance Isn’t as Strong as It Once Was
-
Technology: Strength Continues, With Software Presenting the Best Buying Opportunities
-
Best- and Worst-Performing Stocks of Q3 2024
-
Top Stocks to Own From the Best Fund Managers
-
2 Cheap Stocks Top Managers Have Been Buying
-
The 10 Best Companies to Invest in Now
United States